Datasea Inc (DTSS)

Datasea Intelligent Technology Ltd. (DTSS), a British Virgin Islands holding company operating in China, has filed a Form F-3 shelf registration to offer up to $150 million in mixed securities, including Class A ordinary shares, debt securities, warrants, units, and rights. The filing highlights risks associated with its Variable Interest Entity (VIE) structure, Chinese regulations, and the Holding Foreign Companies Accountable Act. Datasea's business focuses on acoustic intelligence and AI-driven multimodal digitalization, with significant revenue growth reported for fiscal year 2025.

Datasea Intelligent Technology Ltd. announced that its variable interest entity has registered its NeuroVibe Biofeedback System (products NV-02 and NV-03) with the U.S. FDA. The system is listed as Class II 510(k)-exempt medical devices for neurology and integrates acoustic stimulation, transcranial vibro-acoustic stimulation, EEG signal acquisition, and AI for health management. Datasea plans to focus early commercialization efforts in the U.S. on regulatory-compliant applications for brain health, stress relaxation, sleep improvement, and cognitive maintenance.

Datasea Intelligent Technology Ltd. (NASDAQ:DTSS) announced that its NeuroVibe Biofeedback System, including products NV-02 and NV-03, has completed establishment registration and device listing with the U.S. Food and FDA. The NeuroVibe system is a non-invasive biofeedback platform integrating acoustic stimulation, transcranial vibro-acoustic stimulation, electroencephalogram signal acquisition, and AI-assisted health management. This registration marks an important step in Datasea's international commercialization strategy, with initial efforts focusing on brain health management, biofeedback training, stress relaxation, sleep improvement, and cognitive maintenance in the U.S. market.

Datasea Intelligent Technology Ltd. (NASDAQ:DTSS) announced that its NeuroVibe Biofeedback System, including products NV-02 and NV-03, has completed establishment registration and device listing with the U.S. Food and Drug Administration (FDA). The NeuroVibe system is a non-invasive biofeedback platform designed for neurological function assessment and training, integrating acoustic stimulation, transcranial vibro-acoustic stimulation, electroencephalogram signal acquisition, and AI-assisted health management. This registration marks a crucial step in Datasea's international commercialization strategy, targeting applications such as brain health management, stress relaxation, sleep improvement, and cognitive maintenance in the U.S. market.

Datasea Intelligent Technology Ltd. announced that its NeuroVibe Biofeedback System (NV-02 and NV-03) has completed FDA establishment registration and device listing as Class II 510(k)-exempt biofeedback medical devices. This milestone advances NeuroVibe, which integrates acoustic AI and non-invasive brain-computer interface technology, from R&D towards commercial deployment and strengthens Datasea's position in brain health technology. The system aims to provide non-pharmacological interventions for applications like brain health management, stress relaxation, and cognitive maintenance.